Evidence map›Paper›PMID 36344668›Full record

ArticleAnalytical and bioanalytical chemistry2023

First bioelectronic immunoplatform for quantitative secretomic analysis of total and metastasis-driven glycosylated haptoglobin.

Cristina Muñoz-San Martín, Ana Montero-Calle, María Garranzo-Asensio, Maria Gamella, Víctor Pérez-Ginés, María Pedrero, José M Pingarrón, Rodrigo Barderas, Noemí de-Los-Santos-Álvarez, María Jesús Lobo-Castañón and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Cristina Muñoz-San MartínDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain.ORCID https://orcid.org/0000-0002-8324-0709
Ana Montero-CalleUFIEC, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.ORCID https://orcid.org/0000-0001-5141-0454
María Garranzo-AsensioUFIEC, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain.ORCID https://orcid.org/0000-0003-0850-4986
Maria GamellaDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain.ORCID https://orcid.org/0000-0002-5408-118X
Víctor Pérez-GinésDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain.ORCID https://orcid.org/0000-0003-4690-7663
María PedreroDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain.ORCID https://orcid.org/0000-0002-2047-396X
José M PingarrónDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain.ORCID https://orcid.org/0000-0003-2271-1383
Rodrigo BarderasUFIEC, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain. r.barderasm@isciii.es.ORCID https://orcid.org/0000-0003-3539-7469
Noemí de-Los-Santos-ÁlvarezDepartamento de Química Física y Analítica, Universidad de Oviedo, 33006, Oviedo, Spain.ORCID https://orcid.org/0000-0002-5216-6825
María Jesús Lobo-CastañónDepartamento de Química Física y Analítica, Universidad de Oviedo, 33006, Oviedo, Spain. mjlc@uniovi.es.ORCID https://orcid.org/0000-0002-2964-9490
Susana CampuzanoDepartamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, 28040, Madrid, Spain. susanacr@quim.ucm.es.ORCID https://orcid.org/0000-0002-9928-6613
Universidad Complutense de Madrid · ESInstituto de Salud Carlos III · ESUniversidad de Oviedo · ES

Funding

AES-ISCIII Program PI20CIII/00019Comunidad de Madrid S2018/NMT-4349Ministerio de Ciencia e Innovación RTI-2018-095756-B-I00
6 · The paper itself

Abstract

The glycosylation status of proteins is increasingly used as biomarker to improve the reliability in the diagnosis and prognosis of diseases as relevant as cancer. This feeds the need for tools that allow its simple and reliable analysis and are compatible with applicability in the clinic. With this objective in mind, this work reports the first bioelectronic immunoplatforms described to date for the determination of glycosylated haptoglobin (Hp) and the simultaneous determination of total and glycosylated Hp. The bioelectronic immunoplatform is based on the implementation of non-competitive bioassays using two different antibodies or an antibody and a lectin on the surface of commercial magnetic microcarriers. The resulting bioconjugates are labeled with the horseradish peroxidase (HRP) enzyme, and after their magnetic capture on disposable electroplatforms, the amperometric transduction using the H

Indexed as

Biosensing TechniquesNeoplasmsAntibodiesEnzyme-Linked Immunosorbent AssayHaptoglobinsHumansHydrogen PeroxideReproducibility of ResultsAntibodiesHaptoglobinsHydrogen PeroxideAmperometryGlycosylated haptoglobinMetastatic CRC cellsMultiplexed immunoplatformSecretome

Identifiers

PMID36344668
PMCPMC10079713
OpenAlexW4308396218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.